Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
universal anti-CD19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Universal anti-CD19 CAR-T cells, specifically referring to Gracell Biotechnologies' GC027 (TruUCAR-19), are an investigational, off-the-shelf (allogeneic) chimeric antigen receptor T-cell therapy designed to target CD19-expressing B-cell malignancies. Unlike traditional autologous CAR-T therapies that require manufacturing from a patient's own cells, GC027 is derived from healthy donor T cells. This approach utilizes the proprietary TruUCAR platform, which employs gene-editing technology to knock out the T-cell receptor (TCR) and HLA class I molecules to minimize the risk of graft-versus-host disease (GvHD) and host-versus-graft (HvG) rejection. This 'universal' design allows for immediate treatment availability and potentially more consistent product quality. GC027 is primarily being evaluated in clinical trials for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphomas.
- Other names
- allogeneic CD19 CAR-T cellsoff-the-shelf CD19 CAR-Tuniversal anti-CD19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on universal anti-CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on universal anti-CD19 CAR-T cells.